Biota's HRV drug starts dosing for phase 1b clinical trial

By Elaine Rigoli

Tampa, Fla., Aug. 17 - Biota Holdings Ltd. announced the first dose administration in 32 healthy volunteers in its phase 1b clinical trial for its human rhinovirus (HRV) drug BTA798.

The company said BTA798 is an antiviral for the treatment of HRV, the common cold virus, known to cause significant clinical complications in sufferers of asthma and chronic obstructive pulmonary disease, the fourth leading cause of death in the United States.

The primary objective of the trial is to assess the safety and tolerability of BTA798, with a secondary objective to determine the pharmacokinetic properties of the drug over multiple doses.

The phase 1b trial, conducted in the United Kingdom, is the second of two parts of the phase 1 clinical trial that started in February. Phase 1a was successfully completed with BTA798 and found to be safe and well-tolerated in healthy volunteers.

Biota is an antiviral drug-development company in Melbourne, Australia.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.